Welcome to our dedicated page for Dermata Therapeutics news (Ticker: DRMA), a resource for investors and traders seeking the latest updates and insights on Dermata Therapeutics stock.
Dermata Therapeutics Inc (DRMA) is a clinical-stage biotechnology company advancing topical treatments for dermatological conditions through its proprietary Spongilla technology. This page aggregates all official press releases, regulatory filings, and news coverage related to the company's clinical programs and corporate developments.
Investors and industry stakeholders will find timely updates on Phase 3 trial progress, FDA communications, and strategic partnerships. Our curated news feed ensures access to verified information about DRMA's innovative approaches to treating acne, rosacea, and other skin conditions.
The archive includes updates across key categories: clinical trial results, intellectual property milestones, product pipeline advancements, and financial disclosures. Each entry provides context about Dermata's unique position in medical dermatology and aesthetic treatments.
Bookmark this page for direct access to DRMA's latest developments. Regular updates offer essential insights for tracking the company's progress in bringing novel topical therapies to market.
Dermata Therapeutics (NASDAQ:DRMA) has announced additional positive results from its Phase 3 STAR-1 trial for XYNGARI™, a potential first-ever once-weekly topical treatment for moderate-to-severe acne. The trial demonstrated statistically significant efficacy after just four treatments at week 4.
Key results at week 4 showed:
- 11.9% of XYNGARI™ patients achieved IGA treatment success vs 6.2% for placebo (p<0.05)
- Mean inflammatory lesion count reduction of -11.4 for XYNGARI™ vs -8.6 for placebo (p<0.001)
- Mean non-inflammatory lesion count reduction of -12.4 for XYNGARI™ vs -8.8 for placebo (p<0.001)
The STAR-1 study enrolled 520 patients aged 9+ years across the US and Latin America in a 2:1 randomized, double-blind, placebo-controlled trial. This is the first of two pivotal Phase 3 studies, with successful results potentially supporting a future FDA new drug application.
Dermata Therapeutics (NASDAQ:DRMA) has secured $6.2 million in gross proceeds through the immediate exercise of outstanding warrants. The agreement involves the exercise of 4,834,470 warrants at a reduced price of $1.284 per share, down from original exercise prices of $1.58 and $4.91.
In exchange for the immediate cash exercise, Dermata will issue new unregistered warrants: Series A warrants to purchase up to 4,980,806 shares and Series B warrants for up to 4,688,134 shares, both at $1.284 per share. Series A warrants will have a 5-year term, while Series B warrants will expire after 18 months, both pending shareholder approval.
The company plans to use the net proceeds for general corporate purposes, including research, pre-clinical studies, clinical trials, development of new biological and pharmaceutical technologies, potential acquisitions, and working capital. H.C. Wainwright & Co. serves as the exclusive financial advisor for this offering.
Dermata Therapeutics (NASDAQ: DRMA) announced positive topline results from its first pivotal Phase 3 trial of XYNGARI™, a novel once-weekly topical treatment for moderate-to-severe acne. The STAR-1 trial met all three primary endpoints with statistically significant improvements compared to placebo after 12 weeks of treatment.
The randomized, double-blind study enrolled 520 patients aged 9 and older across the US and Latin America. XYNGARI™ demonstrated significant efficacy in Investigator Global Assessment (IGA) treatment success, inflammatory lesion count, and non-inflammatory lesion count. The treatment showed minimal adverse events with no serious events attributed to it.
Following these results, Dermata plans to initiate the second Phase 3 STAR-2 trial in the second half of 2025, followed by an open-label extension study. If successful, the Phase 3 program will support a new drug application with the FDA. The company is pursuing discussions with potential partners for XYNGARI™'s future rights.
Dermata Therapeutics (NASDAQ:DRMA) provided its year-end 2024 financial results and corporate updates. The company expects to announce topline results from its XYNGARI™ Phase 3 STAR-1 clinical trial for moderate-to-severe acne by end of March 2025.
Key financial highlights include:
- Cash position of $3.2M as of December 31, 2024
- R&D expenses increased to $8.2M in 2024 from $4.1M in 2023
- G&A expenses rose to $4.3M from $4.0M year-over-year
- Raised $7.8M in gross proceeds during 2024
Notable developments include a Clinical Trial Collaboration Agreement with Revance Therapeutics to study DMT410 for axillary hyperhidrosis treatment, and a $2.55M private placement in January 2025. The company expects current cash resources to fund operations into Q3 2025.
Dermata Therapeutics (NASDAQ: DRMA) has announced the completion of the last patient visit in their pivotal Phase 3 STAR-1 clinical trial for XYNGARI™, a novel once-weekly topical treatment for moderate-to-severe acne. The trial enrolled 520 patients across the U.S. and Latin America, with topline results expected by end of March 2025.
The STAR-1 study is a randomized (2:1), double-blind, placebo-controlled trial evaluating XYNGARI's efficacy, safety, and tolerability. Primary endpoints include changes in inflammatory and noninflammatory lesion counts and Investigator Global Assessment (IGA) treatment response. The treatment period lasted 12 weeks, with monthly evaluations.
XYNGARI™ targets multiple acne mechanisms, including inflammation reduction and pore unclogging. With over 30 million acne patients seeking treatment annually in the U.S., this represents the first of two pivotal Phase 3 studies required for FDA new drug application submission.
Dermata Therapeutics (NASDAQ: DRMA) announced the Australian Patent Office has accepted its patent application for the DMT410 program for treating hyperhidrosis. This would be Dermata's second patent for DMT410, which uses Spongilla technology to topically deliver botulinum toxin for excessive sweating treatment.
The Company recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 for axillary hyperhidrosis. The upcoming Phase 2a study will explore DMT410's combination of a single XYNGARI™ application followed by a topical application of DAXXIFY®.
Gerry Proehl, Dermata's Chairman, President, and CEO, stated the acceptance further validates DMT410's innovative approach. Beyond hyperhidrosis, the company believes DMT410 holds promise for treating various skin conditions, including acne, rosacea, melasma, acne scars, and other aesthetic concerns.
The patent, entitled "Compositions for the treatment of skin conditions," will be automatically issued three months after acceptance unless opposed by a third party. Dermata also has an issued patent in Japan covering their DMT410 program for hyperhidrosis treatment.
Dermata Therapeutics (NASDAQ:DRMA), a late-stage biotechnology company focused on skin diseases and conditions, has announced an upcoming presentation on BioPub on January 31, 2025, at 12:00PM ET. The interactive online event will feature CEO Gerry Proehl and Chief Development Officer Chris Nardo, Ph.D., who will provide updates on key developments.
The presentation will cover the ongoing XYNGARI™ STAR-1 Phase 3 clinical trial, with topline results expected in March 2025, and discuss their recent collaboration agreement with Revance Therapeutics. Shareholders and investors will have the opportunity to interact with management and ask questions in real-time.
For those unable to attend the live event, an archived webcast will be available on BioPub and Torrey Hills Capital.
Dermata Therapeutics (NASDAQ:DRMA) has closed a private placement offering, raising $2.55 million through the issuance of 2,007,880 shares of common stock and accompanying warrants. The offering was priced at $1.27 per share, at-the-market under Nasdaq rules.
The warrants, also exercisable at $1.27 per share, will become active upon stockholder approval and expire after five years. Company insiders, including the CEO, CFO, and board members, participated in the offering at the same price as other investors. H.C. Wainwright & Co. served as the exclusive placement agent.
The net proceeds, combined with existing cash, are expected to fund operations into Q3 2025. The funds will support research, clinical trials, technology development, potential acquisitions, and working capital. The securities were offered under Section 4(a)(2) of the Securities Act and have not been registered, with the company agreeing to file a resale registration statement.
Dermata Therapeutics (NASDAQ:DRMA) has announced a private placement offering priced at-the-market, raising approximately $2.55 million through the sale of 2,007,880 shares of common stock and accompanying warrants. The transaction is priced at $1.27 per share, with warrants having the same exercise price and a five-year expiration term from stockholder approval.
Company insiders, including the CEO, CFO, and board members, are participating in the offering at the same purchase price as other investors. H.C. Wainwright & Co. is serving as the exclusive placement agent. The closing is expected around January 23, 2025.
The funds will be used for general corporate purposes, including research, pre-clinical studies, clinical trials, technology development, potential acquisitions, and working capital. The securities are being offered under Section 4(a)(2) of the Securities Act and have not been registered, with the company agreeing to file a resale registration statement.
Dermata Therapeutics (NASDAQ:DRMA) and Revance Therapeutics (NASDAQ:RVNC) have announced a clinical trial collaboration to evaluate the topical application of Xyngari™ with Daxxify® for treating primary axillary hyperhidrosis. The companies will initiate a Phase 2a clinical trial involving approximately 48 patients across U.S. sites.
The randomized, double-blind, placebo-controlled trial will assess efficacy, safety, and tolerability over 16 weeks. The study aims to develop the first approved needle-free intradermal delivery of a botulinum toxin product. The trial will measure sweat reduction and evaluate patients at 4 regular intervals.
Xyngari's microscopic spicules create microchannels in the dermis for botulinum toxin delivery, potentially offering an alternative to traditional needle injections. Previous Phase 1 trials of Xyngari with botulinum toxin showed promising efficacy and safety results for both hyperhidrosis and aesthetic skin conditions.
FAQ
What is the current stock price of Dermata Therapeutics (DRMA)?
What is the market cap of Dermata Therapeutics (DRMA)?
